Impact of stewardship on inhaled nitric oxide utilization in a neonatal ICU

Hospital Pediatrics

Volumn 6, Issue 10, 2016, Pages 607-615

  Elmekkawi, Amir ^a   More, Kiran ^b   Shea, Jennifer ^a   Sperling, Christina ^a   Da Silva, Zelia ^a   Finelli, Michael ^a   Rolnitsky, Asaph ^c   Jankov, Robert P ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CHRISTCHURCH WOMEN S HOSPITAL   (New Zealand)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ARTICLE; CLINICAL AUDIT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; EXTRACORPOREAL OXYGENATION; FEMALE; GESTATIONAL AGE; HEALTH CARE UTILIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEONATAL INTENSIVE CARE UNIT; OFF LABEL DRUG USE; PREMATURITY; PROTOCOL COMPLIANCE; PULMONARY HYPERTENSION; RESPIRATORY CARE; RETROSPECTIVE STUDY; TOTAL QUALITY MANAGEMENT; VENTILATOR WEANING; CANADA; CLINICAL PATHWAY; HEALTH SERVICE; NEWBORN; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL; PROCEDURES; RESPIRATORY INSUFFICIENCY; STANDARDS; STATISTICS AND NUMERICAL DATA; UTILIZATION;

CANADA; CRITICAL PATHWAYS; EVIDENCE-BASED PRACTICE; FEMALE; GUIDELINE ADHERENCE; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; MEDICAL OVERUSE; NITRIC OXIDE; QUALITY IMPROVEMENT; RESPIRATORY INSUFFICIENCY; RESPIRATORY THERAPY;

EID: 85015693525     PISSN: 21541663     EISSN: 21541671     Source Type: Journal    
DOI: 10.1542/hpeds.2016-0003     Document Type: Article

References (43)

1. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol. 2005;29(1):8-14
2. Steinhorn RH, Millard SL, Morin FC III. Persistent pulmonary hypertension of the newborn. Role of nitric oxide and endothelin in pathophysiology and treatment. Clin Perinatol. 1995;22(2):405-428
3. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340(8823):819-820
4. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340(8823):818-819
5. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336(9):597-604
6. Roberts JD Jr, Fineman JR, Morin FC III, et al; The Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med. 1997;336(9):605-610
7. Clark RH, Kueser TJ, Walker MW, et al; Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342(7):469-474
8. Day RW, Lynch JM, White KS, Ward RM. Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics. 1996;98(4 pt 1):698-705
9. Inhaled nitric oxide in term and nearterm infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr. 2000;136(5):611-617
10. Clark RH, Huckaby JL, Kueser TJ, et al; Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J Perinatol. 2003;23(4):300-303
11. Hintz SR, Van Meurs KP, Perritt R, Poole WK, Das A, Stevenson DK, et al. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. J Pediatr. 2007;151(1):16-22
12. Konduri GG, Vohr B, Robertson C, et al; Neonatal Inhaled Nitric Oxide Study Group. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. J Pediatr. 2007;150(3):235-240.e1
13. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2006; (4):CD000399
14. Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. Toxicol Sci. 2001;59(1):5-16
15. Cheung PY, Salas E, Etches PC, Phillipos E, Schulz R, Radomski MW. Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates. Lancet. 1998;351(9110):1181-1182
16. George TN, Johnson KJ, Bates JN, Segar JL. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr. 1998;132(4):731-734
17. Souza JM, Peluffo G, Radi R. Protein tyrosine nitration-functional alteration or just a biomarker? Free Radic Biol Med. 2008;45(4):357-366
18. Zou M, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem. 1997;378(7):707-713
19. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271(5 pt 1):C1424-C1437
20. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990;87(4):1620-1624
21. Ellsworth MA, Harris MN, Carey WA, Spitzer AR, Clark RH. Off-label use of inhaled nitric oxide after release of NIH consensus statement. Pediatrics. 2015;135(4):643-648
22. Van Meurs KP, Wright LL, Ehrenkranz RA, et al; Preemie Inhaled Nitric Oxide Study. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353(1):13-22
23. Ballard RA, Truog WE, Cnaan A, et al; NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355(4):343-353
24. Mercier JC, Hummler H, Durrmeyer X, et al; EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet. 2010;376(9738):346-354
25. Askie LM, Ballard RA, Cutter GR, et al; Meta-analysis of Preterm Patients on Inhaled Nitric Oxide Collaboration. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics. 2011;128(4):729-739
26. Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics. 2011;127(2):363-369
27. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2006; (1):CD000509
28. Kumar P; Committee on Fetus and Newborn; American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. Pediatrics. 2014;133(1):164-170
29. Simsic JM, Harrison S, Evans L, McClead R, Teske D; Institute of Healthcare Improvement. Reducing variation in the use of inhaled nitric oxide. Pediatrics. 2014;133(6). Available at: www.pediatrics.org/cgi/content/full/133/6/e1753
30. Coulter S, Merollini K, Roberts JA, Graves N, Halton K. The need for costeffectiveness analyses of antimicrobial stewardship programmes: A structured review. Int J Antimicrob Agents. 2015;46(2):140-149
31. Amerine LB, Chen SL, Daniels R, Key N, Eckel SF, Savage SW. Impact of an innovative blood factor stewardship program on drug expense and patient care. Am J Health Syst Pharm. 2015;72(18):1579-1584
32. Ghafoor VL, Phelps P, Pastor J. Implementation of a pain medication stewardship program. Am J Health Syst Pharm. 2013;70(23):2070-2075
33. Benneyan JC, Lloyd RC, Plsek PE. Statistical process control as a tool for research and healthcare improvement. Qual Saf Health Care. 2003;12(6):458-464
34. Woolf SH. Practice guidelines: a new reality in medicine. I. Recent developments. Arch Intern Med. 1990;150(9):1811-1818
35. Di Pentima MC, Chan S. Impact of antimicrobial stewardship program on vancomycin use in a pediatric teaching hospital. Pediatr Infect Dis J. 2010;29(8):707-711
36. Kumar VH, Hutchison AA, Lakshminrusimha S, Morin FC III, Wynn RJ, Ryan RM. Characteristics of pulmonary hypertension in preterm neonates. J Perinatol. 2007;27(4):214-219
37. Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed. 1997;77(3):F185-F190
38. Kinsella JP, Walsh WF, Bose CL, et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet. 1999;354(9184):1061-1065
39. Truffert P, Llado-Paris J, Mercier JC, Dehan M, Bréart G; Franco-Belgian iNO Study Group. Early inhaled nitric oxide in moderately hypoxemic preterm and term newborns with RDS: the RDS subgroup analysis of the Franco-Belgian iNO Randomized Trial. Eur J Pediatr. 2003;162(9):646-647
40. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349(22):2099-2107
41. Kahveci H, Yilmaz O, Avsar UZ, et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. Pediatr Pulmonol. 2014;49(12):1205-1213
42. Crossing the Quality Chasm. A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001
43. http://ken.caphc.org/xwiki/bin/view/PaediatricPracticeGuidelinesCollaborative/CAPHC1Guidelines1for1Inhaled1Nitric1Oxide1in1Neonates%3A11Dosing,1Administration1and1Weaning